Chronic Immune Thrombocytopenic Purpura

Slide 1 · Chronic Immune Thrombocytopenic Purpura

Immune platelet clearance • marrow response • clinical and diagnostic pathology

A pathology lecture integrating disease mechanisms with diagnostic reasoning

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain immune platelet destruction and impaired platelet production in chronic ITP.

Correlate blood, marrow, and splenic findings with accelerated thrombopoiesis.

Recognize characteristic bleeding patterns and laboratory findings.

Differentiate primary ITP from secondary, consumptive, and production disorders.

Relate treatments to the pathogenetic steps they influence.

Slide 3 · Core definition

Autoantibody-mediated platelet destruction

Chronic ITP is an immune thrombocytopenia dominated by accelerated platelet clearance.

The disorder may be primary or arise with a recognized associated condition.

In some patients, antibodies also damage megakaryocytes, reducing platelet production.

Slide 4 · Platelets participate in primary hemostasis

Vascular injury

Exposes adhesive targets

Platelet plug

Platelets adhere and aggregate

Coagulation

Platelets support secondary hemostasis

Stable clot

Fibrin reinforces the plug

A low platelet count chiefly compromises the initial platelet-dependent response.

Slide 5 · Why thrombocytopenia bleeds differently

Platelet-number defect

Small-vessel hemorrhage

Skin and mucosal bleeding

Petechiae, purpura, epistaxis

Coagulation-pathway defect

Typically assessed through PT/PTT

Abnormalities may prolong clotting assays

A separate diagnostic pathway

The distinction is conceptual; Bleeding disorders may also overlap.

Slide 6 · Platelet counts and bleeding context

Platelet count

Teaching interpretation

<150,000/µL

Usually classified as thrombocytopenia

20,000–50,000/µL

May aggravate bleeding after trauma

<20,000/µL

May be associated with spontaneous bleeding

Thresholds describe broad risk patterns, not a patient-specific treatment rule.

Slide 7 · Four broad mechanisms of thrombocytopenia

Mechanism

Characteristic process

Reduced production

Bone marrow or megakaryocyte output is impaired

Reduced survival

Immune destruction or nonimmune platelet consumption

Sequestration

Platelets accumulate in an enlarged spleen

Dilution

Massive transfusion decreases platelet concentration

Chronic ITP is primarily a disorder of immune-mediated platelet survival.

Slide 8 · Where chronic ITP fits in the differential

Thrombocytopenia

Platelet count reduced

Decreased survival

Shortened platelet lifespan

Immune mechanism

Antibody binding/opsonization

Chronic ITP

Platelet clearance ± impaired output

Slide 9 · Primary versus secondary chronic ITP

Primary ITP

No identified predisposing disease or exposure

Diagnosis requires excluding secondary causes

“Idiopathic” is a historical alternative term

Secondary ITP

Occurs with another condition or exposure

Immune mechanism still affects platelets

Associated disease modifies diagnostic reasoning

Slide 10 · Established secondary associations

Systemic lupus erythematosus

Autoimmune disease context can accompany immune platelet loss.

HIV infection

Both immune platelet clearance and impaired megakaryocyte output may occur.

B-cell neoplasms

Chronic lymphocytic leukemia is a specified example.

Slide 11 · Primary ITP is a diagnosis of exclusion

Document

True thrombocytopenia

Characterize

Pattern, smear and hemostatic tests

Investigate

Secondary and alternative causes

Conclude

Primary ITP only after exclusion

There is no single positive test that establishes primary ITP.

Slide 12 · Platelet membrane glycoproteins are immune targets

Platelet membrane

Common autoantibody targets

Glycoprotein IIb/IIIa

Glycoprotein Ib/IX

Slide 13 · The dominant antibody class is IgG

Antiplatelet IgG marks circulating platelets for removal

Autoantibodies commonly bind platelet membrane glycoproteins IIb/IIIa or Ib/IX.

Antibody-mediated opsonization is the link from autoreactivity to clearance.

The mechanistic analogy is autoimmune hemolytic anemia.

Slide 14 · Fc receptor recognition drives clearance

IgG-opsonized platelet

Splenic macrophage

IgG Fc receptor-mediated recognition

Schematic — not a microscopy image

Slide 15 · Opsonization to platelet removal

IgG binding

Autoantibody binds platelet surface

Fc recognition

Phagocyte recognizes exposed IgG Fc

Phagocytosis

Opsonized platelet is removed

Net effect

Shortened platelet survival

Slide 16 · The spleen is the principal clearance site

Splenic phagocytes remove opsonized platelets

Marked platelet improvement after splenectomy provides functional evidence.

Antibody-coated platelets are cleared through IgG Fc receptor pathways.

This is accelerated platelet destruction, not primary failure of coagulation.

Slide 17 · The spleen has two relevant roles

Platelet clearance

Phagocytes recognize IgG-coated platelets

Removal reduces platelet survival

Dominant effect in the pathogenesis

Antibody contribution

Red pulp contains numerous plasma cells

Some of the benefit after splenectomy may reflect antibody-source removal

This is presented as a possible additional mechanism

Slide 18 · Some antibodies also affect megakaryocytes

Autoreactive IgG

May bind megakaryocytes

Cell injury

Megakaryocytes can be damaged

Lower output

Platelet production falls

Amplification

Thrombocytopenia worsens

Slide 19 · Two interacting causes of the platelet deficit

Increased loss

Platelets opsonized by autoantibodies

Splenic macrophage uptake

Shorter circulating survival

Impaired replacement

Autoantibodies may injure megakaryocytes

Platelet production may decrease

Marrow compensation can become inadequate

Slide 20 · The net platelet count reflects opposing processes

Immune destruction

Peripheral loss increases

Marrow response

Thrombopoiesis accelerates

Variable injury

Megakaryocyte output may fall

Observed count

Survival and production both matter

The blood count is the final balance of clearance and output, not a direct assay of either mechanism.

Slide 21 · Mechanism: Observation versus inference

Source observation

What it supports

What it does not prove

IgG binding in ~80%

Autoimmunity often detectable

A negative assay excludes ITP

Response to splenectomy

Spleen is major clearance site

Every patient will be cured

Increased marrow megakaryocytes

Compensatory production

A specific histologic diagnosis

Slide 22 · Typical adult presentation

A predominance in adult women younger than 40 years.

The reported female-to-male ratio is approximately 3:1.

This demographic pattern is supportive context, not a diagnostic criterion.

Neither sex nor age substitutes for demonstrating isolated thrombocytopenia.

Slide 23 · Clinical onset and recognition

Early course

Often insidious

First clues

Bruising or mucosal oozing

Recognition

Low platelet count is identified

Evaluation

Exclude secondary and competing causes

Slide 24 · Why bleeding occurs in small vessels

Platelet deficit

Primary hemostasis impaired

Minor leakage

Capillaries and small vessels bleed

Distribution

Skin/mucosal surfaces

Manifestations

Petechiae and mucosal hemorrhage

Slide 25 · Petechiae can coalesce into larger hemorrhages

Petechiae

Confluent lesions

Schematic pattern only — not a clinical photograph

Slide 26 · Dependent areas favor petechiae

Higher local capillary pressure helps explain distribution

Pinpoint hemorrhages are particularly prominent in dependent skin regions.

The distribution is a hemodynamic consequence superimposed on platelet deficiency.

A visible bleeding pattern does not by itself establish the etiology.

Slide 27 · Ecchymoses and easy bruising

Petechiae can become confluent to form ecchymoses.

Minor trauma may produce bruising out of proportion to the injury.

Soft-tissue hemorrhage may accompany skin and mucosal bleeding.

A precise bleeding history should distinguish spontaneous from trauma-related events.

Slide 28 · Characteristic mucocutaneous symptoms

Nasal / oral

Epistaxis and gingival bleeding may be early complaints.

Skin

Petechiae, purpura and easy bruising are characteristic.

Soft tissues

Relatively minor trauma may produce clinically evident hemorrhage.

Slide 29 · Bleeding may be the first presentation

Gastrointestinal

Melena may be a presenting symptom.

Urinary

Hematuria may disclose the platelet deficit.

Gynecologic

Excessive menstrual flow can be an early clinical clue.

Slide 30 · Rare but serious hemorrhage

Intracranial bleeding is a critical complication

Subarachnoid and intracerebral hemorrhage are described in chronic ITP.

They may be fatal, although they are rare in treated patients.

Severity assessment must not be based on the skin findings alone.

Slide 31 · Examination: What is typical and atypical?

Compatible with primary ITP

Mucocutaneous hemorrhage

Usually normal splenic size

No expected lymphadenopathy

Suggests a competing diagnosis

Splenomegaly

Enlarged lymph nodes

Clinical context of B-cell neoplasm or systemic illness

Slide 32 · Splenomegaly is not expected in primary ITP

An enlarged spleen changes the diagnostic hypothesis

The spleen as normal-sized in uncomplicated chronic ITP.

Marked enlargement suggests alternative mechanisms or an associated disorder.

Hypersplenism and hematologic neoplasms become more relevant.

Slide 33 · Lymphadenopathy warrants explanation

Consider secondary ITP or another disease

Primary chronic ITP ordinarily lacks lymphadenopathy.

example, a B-cell neoplasm may cause secondary immune thrombocytopenia.

Physical findings guide selective evaluation rather than confirming ITP.

Slide 34 · Morphology involves three compartments

Spleen

Normal-sized; Sinusoidal congestion; Reactive follicles; Occasional megakaryocytes.

Bone marrow

Modest megakaryocytic increase, sometimes immature forms.

Peripheral blood

Thrombocytopenia with some unusually large platelets.

Slide 35 · Gross spleen: Usually normal-sized

No characteristic splenic enlargement

A normal-sized spleen is compatible with immune platelet destruction.

Increased phagocytic activity does not require gross splenomegaly.

Organ size alone does not establish or exclude immune clearance.

Slide 36 · Microscopic splenic features

Sinusoids

Congestion may be present in the splenic red pulp.

White pulp follicles

Follicular enlargement with prominent reactive germinal centers.

Sinusoidal megakaryocytes

Occasional cells may reflect mild extramedullary hematopoiesis.

Schematic concept summaries; The textbook findings are not ITP-specific.

Slide 37 · Splenic megakaryocytes: A proposed response

A minor extramedullary hematopoietic component is possible

Scattered megakaryocytes can be found in splenic sinusoids.

The source proposes elevated thrombopoietin as a possible driver.

This hypothesis should not be converted into a disease-specific morphologic criterion.

Slide 38 · Bone marrow: Compensatory megakaryocytopoiesis

Marrow megakaryocyte

Modestly increased megakaryocytes

Some cells show single, large nonlobulated nuclei

Accelerated thrombopoiesis is not ITP-specific

Slide 39 · Immature-appearing megakaryocytes

Some marrow megakaryocytes have large, nonlobulated single nuclei.

A modest increase in megakaryocyte numbers reflects increased platelet turnover.

These findings also appear in other causes of accelerated platelet destruction.

Morphology must be integrated with the clinical and laboratory context.

Slide 40 · Marrow morphology is not specific for ITP

Megakaryocytic hyperplasia supports turnover, not etiology

A similar marrow response can occur in many destructive thrombocytopenias.

The diagnostic value is often exclusion of marrow failure or another marrow disorder.

The marrow should not be called pathognomonic for immune thrombocytopenia.

Slide 41 · Peripheral blood: Large platelets

Schematic peripheral smear

Unusually large platelets = megathrombocytes

Suggest a brisk production response

Not independently diagnostic of ITP

Slide 42 · Why unusually large platelets appear

Immune loss

Circulating platelets removed rapidly

Compensation

Marrow thrombopoiesis accelerates

Blood appearance

Large platelets become conspicuous

Megathrombocytes are a sign of accelerated platelet production, not a unique ITP marker.

Slide 43 · Integrated morphology: Diagnostic meaning

Compartment

Typical observation

Interpretation

Spleen

Normal size, reactive follicles

Compatible but nonspecific

Marrow

Megakaryocytes often increased

Accelerated thrombopoiesis

Peripheral blood

Low count, large platelets

Destruction/compensation pattern

Slide 44 · The initial laboratory checkpoint

CBC

Confirm platelet deficit

Smear

Check platelet clumping and size

Coagulation

Examine PT and PTT

Context

History, examination and exposures

Slide 45 · Exclude artifactual thrombocytopenia

Platelet clumping can produce a falsely low automated count

Automated platelet counts are performed on anticoagulated blood.

Peripheral-smear inspection helps detect platelet aggregates.

A spurious count should not become a diagnosis of ITP.

Slide 46 · Expected laboratory constellation

Finding

Textbook pattern

Interpretation

Platelet count

Reduced

Isolated thrombocytopenia

Smear

Often unusually large platelets

Accelerated thrombopoiesis

PT and PTT

Normal

Preserved tested coagulation pathways

Marrow (when examined)

Normal/increased megakaryocytes

Compatible response; Nonspecific

Slide 47 · Normal PT/PTT: A mechanistic distinction

Platelet deficit

Primary hemostasis impaired

PT / PTT assays

Measure coagulation-factor pathways

Typical ITP

Neither assay is prolonged

Normal PT and PTT do not exclude clinically important platelet-mediated bleeding.

Slide 48 · Why platelet autoantibody tests do not confirm ITP

Biologic finding

Autoantibodies may be shown in plasma or on platelets

The source reports detection in ~80%

Clinical test limitation

Sensitivity and specificity are insufficient

Not clinically useful as a confirmatory test

Negative or positive tests cannot replace exclusion

Slide 49 · The marrow examination has an exclusionary role

Rule out marrow failure or primary marrow pathology

ITP-associated marrow findings are not specific.

Aplastic anemia, myelodysplastic disease and marrow infiltration can reduce platelet production.

Investigate marrow disorders when the clinical picture suggests them.

Slide 50 · Diagnostic exclusion is organized by mechanism

Low platelets

Verify on smear

Production

Assess marrow-related causes

Survival

Distinguish immune from consumptive

Distribution

Consider sequestration/dilution

Etiology

Classify primary vs secondary

Slide 51 · Reduced production versus increased destruction

Dimension

Reduced production

Increased destruction

Primary defect

Marrow platelet output

Platelet survival

Examples

Aplasia, leukemia, MDS

ITP; Nonimmune consumption

Marrow clue

Output may be impaired

Often compensatory megakaryocytes

Smear clue

Depends on marrow disorder

Large platelets may appear

Slide 52 · Distinguish hypersplenism from primary ITP

Hypersplenism

Sequestration increases with splenic enlargement

An enlarged spleen can retain far more circulating platelets

A distributional mechanism

Primary chronic ITP

Immune destruction of IgG-coated platelets

Spleen usually remains normal-sized

Splenic clearance is not equivalent to hypersplenism

Slide 53 · Consumptive thrombocytopenia versus ITP

Feature

Chronic ITP

TMA / DIC

Dominant mechanism

Immune clearance

Excessive consumption

Characteristic context

Isolated platelet deficit

Microvascular thrombi or systemic coagulation

Diagnostic caution

Diagnosis by exclusion

Must not mislabel a dangerous consumption syndrome

Slide 54 · Relevant drug-associated thrombocytopenia

Drug-dependent antibodies

Quinine, quinidine and vancomycin are textbook examples.

GPIIb/IIIa inhibitors

Drug binding may reveal an immunogenic conformation.

Heparin

Immune HIT has a distinctive platelet-activating, thrombotic phenotype.

Slide 55 · HIV-associated platelet loss may be mixed

HIV infection

Megakaryocyte infection can impair output

B-cell dysregulation

Antiplatelet autoantibodies may emerge

Peripheral loss

Opsonized platelets removed

Phenotype

Production plus destruction mechanisms

Slide 56 · Chronic versus acute immune thrombocytopenia

Feature

Chronic ITP (textbook)

Acute ITP (textbook)

Typical group

Adult women <40 y

Children, both sexes

Onset

Often insidious

Abrupt, often after viral illness

Course

May persist or relapse

Usually resolves within 6 months

Mechanism

Autoantibody-mediated

Autoantibody-mediated

This reproduces the textbook comparison; It is not a current formal duration-classification rule.

Slide 57 · Heparin-induced thrombocytopenia is not chronic ITP

Immune HIT (type II)

Antibodies recognize heparin–PF4 complexes

Platelets are activated

Venous and arterial thrombosis can occur

Chronic ITP

Antibodies commonly recognize platelet glycoproteins

Splenic clearance dominates

Mucocutaneous bleeding is characteristic

Slide 58 · TTP is a dangerous alternative diagnosis

Thrombotic microangiopathy

Small-vessel platelet thrombi

Microangiopathic hemolytic anemia is a crucial clue

Requires urgent disease-specific evaluation

Chronic ITP

Predominantly immune platelet clearance

Typical isolated thrombocytopenia

No defining microangiopathic hemolysis

Slide 59 · Integrated diagnostic reasoning

True low count?

Check smear / clumping

Isolated?

Evaluate CBC and PT/PTT

Red flags?

Assess spleen, nodes, consumption

Secondary cause?

Review systemic disease and exposures

Presumptive ITP

Exclusion-based clinical diagnosis

A practical synthesis of the Robbins differential, not an independent guideline algorithm.

Slide 60 · Glucocorticoids target platelet clearance

Glucocorticoid

Inhibits phagocyte function

Reduced uptake

Less removal of opsonized platelets

Platelet count

Often increases

The source reports initial response in almost all patients, with relapse common after withdrawal.

Slide 61 · Why relapse after steroid withdrawal matters

Initial response

Immune clearance is suppressed

Withdrawal

Immune process may persist

Relapse

Platelet count can decline again

An early platelet rise does not ensure durable remission.

Slide 62 · Careful observation can be appropriate

Management follows bleeding severity and longitudinal risk

The textbook permits careful follow-up of some patients with moderately severe thrombocytopenia.

Some patients may enter spontaneous remission.

This pathology overview does not define a numerical management threshold or replace clinical guidelines.

Slide 63 · Splenectomy: Benefit and trade-off

Mechanistic benefit

Removes the principal clearance site

May remove an antibody source

Platelet count normalizes in about two-thirds of severe cases (textbook)

Important cost

Increased risk of bacterial sepsis

Response is not universal

Treatment decisions require individualized clinical assessment

Slide 64 · Immunomodulatory approaches

Intravenous immunoglobulin

An immunomodulatory option described for relapse or splenectomy contraindication.

Anti-CD20 antibody

Rituximab targets B cells as an immune-directed strategy.

Treatment context

The source lists these options without presenting a current stepwise guideline.

Slide 65 · Thrombopoietin-mimetic therapy

TPO mimetic

Peptide or small-molecule agonist

Marrow effect

Stimulates platelet production

Clinical intent

Improves counts in refractory ITP

The therapeutic target is platelet production rather than splenic clearance.

Slide 66 · Treatments map to distinct pathophysiologic targets

Intervention

Mechanistic focus

Textbook qualification

Glucocorticoids

Phagocyte function

Relapse after withdrawal can occur

Splenectomy

Splenic clearance ± antibody source

Sepsis risk; Not uniformly effective

IVIG / rituximab

Immune modulation

Options in relapsed or selected patients

TPO mimetics

Platelet production

May help refractory disease

Slide 67 · Clinical case A: Isolated platelet loss

A 32-year-old woman reports months of easy bruising, gingival bleeding and intermittent epistaxis.

The platelet count is low; Other CBC findings and PT/PTT are not abnormal.

Peripheral blood shows unusually large platelets.

There is no splenomegaly or lymphadenopathy.

Clinical question

Which observations support immune platelet destruction, and what still must be excluded?

Slide 68 · Case A: Evidence chain

Phenotype

Mucocutaneous bleeding

Laboratory

Isolated thrombocytopenia

Compensation

Large peripheral platelets

Conclusion

Chronic ITP is plausible, not proven

A primary diagnosis requires review of secondary, drug-related, marrow, and consumptive causes.

Slide 69 · Clinical case B: Diagnostic redirection

An adult patient has thrombocytopenia together with palpable lymph nodes and splenomegaly.

The bleeding pattern may resemble immune thrombocytopenia.

A B-cell neoplasm is one secondary association.

It is inappropriate to label this uncomplicated primary ITP without further evaluation.

Clinical question

Which examination findings invalidate a simple “primary ITP” shortcut?

Slide 70 · Case B: Classify the context

Platelet deficit

May reflect immune loss

Nodes / spleen

Atypical for primary ITP

Associated condition

Consider B-cell neoplasm

Classification

Secondary ITP or another diagnosis

Slide 71 · Red flags that change the differential

Finding

Implication

Splenomegaly

Consider sequestration, neoplasm or another disorder

Lymphadenopathy

Consider secondary ITP associated with B-cell disease

Platelet aggregates on smear

Consider spurious thrombocytopenia

Microangiopathic hemolysis

Consider TTP/HUS rather than uncomplicated ITP

Marrow failure pattern

Consider impaired production

Slide 72 · Pathology synthesis: Six essential links

Antibody → clearance

IgG-coated platelets are recognized by splenic phagocytes.

Turnover → morphology

Megakaryocytic response and large platelets suggest rapid production.

Platelet loss → bleeding

Skin and mucosal bleeding occur while PT/PTT remain normal.

Primary ITP remains a diagnosis of exclusion; Morphology and antibody testing are not definitive.

Slide 73 · Key references and source limits

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th edition (2026).

Core source: Chronic Immune Thrombocytopenic Purpura; context: thrombocytopenia and adjacent disorders.

All diagrams in this presentation are original native PowerPoint schematics, not diagnostic histologic specimens.

Management content reflects the textbook excerpt, not a separately verified contemporary clinical guideline.